Sutro Biopharma Inc
F:S090
Sutro Biopharma Inc
F:S090
Price:
20.6
EUR
-2.83%
Market Closed
Market Cap:
€175.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Sutro Biopharma Inc
F:S090
|
US |
|
C
|
Cloudflare Inc
XHAN:8CF
|
US |
|
Telkom Indonesia (Persero) Tbk PT
NYSE:TLK
|
ID |
|
W
|
WSFS Financial Corp
XBER:WF4
|
US |
|
WSFS Financial Corp
NASDAQ:WSFS
|
US |
|
E
|
E&E Recycling Inc
TPEX:8440
|
TW |
|
Solteq Oyj
F:B3M
|
FI |
|
F
|
Fuchs Se
XMUN:FPE3
|
DE |
|
Y
|
Yonghe Medical Group Co Ltd
F:L97
|
CN |
|
Franklin BSP Realty Trust Inc
F:6VH
|
US |
|
E
|
Esprinet SpA
F:EP4A
|
IT |
|
Korian SA
F:KO2
|
FR |
|
N
|
Nippon Telegraph and Telephone Corp
F:NTT
|
JP |
|
M
|
Microsoft Corp
MIL:MSFT
|
US |
|
China Construction Bank Corp
F:C6TB
|
CN |
Wall St Price Targets
S090 Price Targets Summary
Sutro Biopharma Inc
Sutro Biopharma Inc
Wall Street analysts forecast S090 stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for S090 is 41.51 EUR with a low forecast of 8.61 EUR and a high forecast of 54.59 EUR.
Lowest Forecast
Price Target
8.61
EUR
58% Downside
Average Forecast
Price Target
41.51
EUR
102% Upside
Highest Forecast
Price Target
54.59
EUR
165% Upside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S090's stock price target?
Price Target
41.51
EUR
41.51
EUR
According to Wall Street analysts, the average 1-year price target for S090 is 41.51 EUR with a low forecast of 8.61 EUR and a high forecast of 54.59 EUR.
What is the Revenue forecast for Sutro Biopharma Inc?
Projected CAGR
20%
20%
Over the last 8 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 20%.
